Reassuring Registry Data on Going Into TAVR Sans Symptoms
Transcatheter aortic valve replacement (TAVR) got some preliminary affirmation for asymptomatic or minimally symptomatic severe aortic stenosis in a retrospective registry study. Of participants who got elective TAVR, the one in five who had minimal symptoms before the procedure tended to have good outcomes that compared favorably against the majority of more symptomatic peers: Fewer […]
PPI Still Common With Self-Expanding TAVR
Need for a pacemaker after transfemoral transcatheter aortic valve replacement (TAVR) with a self-expanding device was both common and impactful for mortality, but the risk appeared to be modifiable, international registry data showed. Of patients treated with an Acurate neo/neo2 (approved outside the U.S.) or Evolut PRO/PRO+ valve, 11.3% needed new permanent pacemaker implantation (PPI) […]
Bicuspid Aortic Valves and Aortopathy Cluster Among Close Relatives
Diagnoses of bicuspid aortic valve (BAV), thoracic aortic aneurysm, and thoracic aortic dissection appeared to run in families extending beyond first-degree relatives, according to the largest pedigree-based study on the subject to date. Among probands with BAV and aortopathy in the Utah Population Database, first-degree relatives were several times more likely to share a concordant […]
Real-World Data Affirms Next-Gen TAVR Device Advantage
PHOENIX — The newer generation Evolut transcatheter aortic valve replacement (TAVR) device improved on procedural and possibly safety characteristics, the TVT registry showed. The Evolut FX device reduced need for device repositioning and cut procedure time, without a change in valve hemodynamics, at 30 days compared with the Evolut Pro+ device, reported Wah Wah Htun, […]
Skipping Antiplatelets Altogether Not Such a Bad Idea for Select TAVR Patients
Following transcatheter aortic valve replacement (TAVR), the optimal antithrombotic regimen for some people may be no antithrombotics at all, according to provocative registry data from Japan. Compared with the single antiplatelet (SAPT) or dual antiplatelet (DAPT) approaches for TAVR patients without any other indications for antiplatelet or anticoagulation therapy, the non-antithrombotic strategy was not associated […]
Aortic Aneurysm Score Paves the Way for More Targeted Screening
Efforts to screen for ascending aortic enlargement in the general population may be improved using a new prediction model based on common clinical variables easily gathered from medical records, researchers found. The AORTA clinical score was found to correlate with measured ascending aortic diameters in development from a large U.K. Biobank cohort and externally validation […]
Is TAVR in Small Aortic Annuli Better With Self-Expanding Valves?
BOSTON — Transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli had better hemodynamic results with a self-expandable than a balloon-expandable valve, with suggestion of better clinical outcomes too, in the France-TAVI registry. Mean gradient was significantly lower with self-expanding Medtronic CoreValve Evolut Pro or R devices at the end of the procedure […]
TAVR Chugging Along at 5 Years in SURTAVI Trial
Researchers keeping an eye on the long-term outcomes of people undergoing transcatheter aortic valve replacement (TAVR) reported encouraging results in both clinical and economic terms, according to two reports from the Transcatheter Cardiovascular Therapeutics (TCT) meeting. The 5-year incidence of all-cause mortality or disabling stroke among people in the SURTAVI trial was no different between […]
Low Risk and Bicuspid Anatomy: A Passable Combination for TAVR Thus Far
People with bicuspid aortic stenosis and low surgical risk did not appear to be at a disadvantage for short-term outcomes after transcatheter aortic valve replacement (TAVR), though longer follow-up and randomized study were urged for such a relatively young cohort. Drawing upon the Transcatheter Valve Therapies (TVT) Registry, investigators found no significant differences in clinical […]